Irbesartan, Metoprolol Succinate

Irbesartan and Metoprolol Succinate is a combination medication that serves two primary purposes in treating patients. Irbesartan, also known as Avapro, is an angiotensin receptor blocker (ARB) that works by inhibiting the angiotensin II receptor in the blood vessels. This results in the relaxation and widening of the blood vessels, leading to lower blood pressure.
Metoprolol Succinate, on the other hand, is a selective beta-1 adrenergic receptor blocker (betablocker) belonging to the class of medications known as beta-blockers. It works by slowing down the heart rate and reducing the heart’s workload, thereby reducing the severity of angina pectoris (chest pain) and decreasing the risk of heart attacks and heart-related complications.
This combination medication is primarily used in patients diagnosed with hypertension (high blood pressure) or coronary artery disease (CAD), specifically those with hypertension and angina pectoris. The combination of Irbesartan and Metoprolol Succinate offers a comprehensive approach to managing these conditions by simultaneously lowering blood pressure and reducing the frequency and intensity of chest pain.